Top Page
Abingdon Health PLC
(LSE:ABDX)
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
Abingdon Health PLC Business Overview & Revenue Model
Abingdon Health PLC Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.43M | 8.43M | 4.04M | 6.13M | 2.83M | 11.62M |
| Gross Profit | 3.13M | 3.13M | 1.40M | 3.68M | -5.23M | 3.39M |
| EBITDA | -2.80M | -3.12M | -2.81M | -916.00K | -19.98M | -6.07M |
| Net Income | -3.42M | -3.42M | -3.47M | -1.27M | -21.26M | -6.97M |
Balance Sheet | ||||||
| Total Assets | 9.31M | 9.31M | 6.06M | 5.09M | 12.77M | 33.23M |
| Cash, Cash Equivalents and Short-Term Investments | 1.92M | 1.92M | 3.24M | 1.44M | 2.40M | 4.98M |
| Total Debt | 1.03M | 1.03M | 1.02M | 1.05M | 1.28M | 1.50M |
| Total Liabilities | 4.01M | 4.01M | 3.05M | 2.84M | 6.34M | 11.90M |
| Stockholders Equity | 5.30M | 5.30M | 3.01M | 2.25M | 6.43M | 21.33M |
Cash Flow | ||||||
| Free Cash Flow | -3.43M | -3.43M | 845.00K | -1.70M | -8.49M | -20.13M |
| Operating Cash Flow | -3.10M | -3.10M | 1.00M | -1.66M | -7.74M | -12.88M |
| Investing Cash Flow | -1.53M | -1.43M | -156.00K | -23.00K | -760.00K | -7.28M |
| Financing Cash Flow | 5.11M | 5.08M | -7.00K | -114.00K | 5.92M | 20.74M |
Abingdon Health PLC Technical Analysis
Abingdon Health PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £280.85M | 53.33 | 6.70% | 3.40% | 17.95% | -54.68% | |
67 Neutral | £106.30M | 18.22 | 8.71% | ― | -1.43% | 28.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.52M | 3.33 | 13.26% | ― | -10.20% | 714.29% | |
47 Neutral | £11.07M | -1.16 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £15.06M | -6.32 | -90.48% | ― | 37.39% | -126.19% | |
43 Neutral | £25.13M | -0.40 | 425.97% | ― | -4.48% | 61.09% |
Abingdon Health PLC Corporate Events
Abingdon Health reported a 45% rise in first-half FY26 revenues to £4.5m, underpinned by several major commercial contracts and grant-funded development work, while cash more than doubled to £3.6m following an October equity raise of £3.2m to fund its US expansion and support higher-value projects. The board reaffirmed full-year FY26 revenue guidance of £12.6m despite deferring revenue from key customer Find Out From Home into FY27, and said it expects a profitable, cash-generative second half as it scales lateral flow development and manufacturing capacity at its Madison, Wisconsin facility, reinforcing confidence in the company’s growth trajectory and commercial momentum.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc, a specialist in rapid diagnostic test development and med-tech regulatory services, has appointed Cavendish Capital Markets Limited as its sole corporate broker and nominated adviser with immediate effect. The move consolidates the company’s advisory and broking relationships under a single City firm, potentially streamlining its access to capital markets and investor engagement as it pursues growth in the international diagnostics and medical device sectors.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc, an international developer and manufacturer of rapid lateral flow tests and related regulatory and analytical services, has announced the issuance and admission to trading on AIM of 5,208 new ordinary shares following the exercise of employee share options. The move is a routine capital markets event that increases the company’s total shares in issue to 251,077,850, with no treasury shares held, and provides an updated share capital figure for investors and other stakeholders to use when assessing and disclosing their interests under UK regulatory transparency rules.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC has secured a European patent for its AppDx® lateral flow smartphone reader, which enables the analysis of lateral flow test results via a smartphone’s camera using advanced image processing and deep learning algorithms. This patent further strengthens the company’s intellectual property portfolio and highlights its innovative role in the lateral flow diagnostics industry, supporting its customers with cutting-edge technologies and reinforcing its market positioning.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC announced that all resolutions were passed with over 99.7% of votes in favor at its recent Annual General Meeting. This strong shareholder support underscores confidence in the company’s strategic direction and operational capabilities, potentially strengthening its position in the med-tech industry and reassuring stakeholders of its continued growth and innovation.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC announced updates to its Long Term Incentive Plan (LTIP), with 16% of the share options awarded in December 2022 now vested based on performance criteria for the financial year ending June 2025. The company has also awarded new LTIPs totaling 3,361,000 shares, set to vest in October 2028, contingent on meeting revenue and EBITDA targets. This move aims to align the interests of directors and senior management with shareholders, potentially impacting company operations and stakeholder interests by incentivizing performance and retention.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC has announced the date for its Annual General Meeting, which will take place on December 10, 2025, at its York Biotech Campus offices. The company has also published its 2025 Annual Report, which is available to shareholders and on its website. This announcement is part of Abingdon Health’s ongoing efforts to maintain transparency and engage with its stakeholders, reinforcing its position as a key player in the med-tech industry.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health plc reported significant growth and expansion in its final results for the financial year ending June 30, 2025. The company secured several large contracts, expanded its CDMO service offerings, and opened new facilities in the UK and USA, contributing to a 40% increase in revenue to £8.6m. Despite an operating loss of £3.5m, the company is optimistic about future growth, supported by recent successful fundraisings and strategic partnerships. The new financial year has started strong, with Q1 revenue ahead of the previous period, indicating continued momentum and potential for further expansion.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC has secured a significant contract valued at approximately US$2 million with a US-based company for the development and manufacturing scale-up of a semi-quantitative, multiplex lateral flow test system. This contract highlights the company’s robust CDMO capabilities and its strategic expansion in the USA, particularly in Madison, Wisconsin, to meet growing demand. The project, expected to span 24 months, underscores Abingdon Health’s ability to support clients from concept to commercial success, enhancing its market positioning and offering comprehensive regulatory and manufacturing services.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC has launched a seaweed-based alternative for lateral flow test housings, aiming to reduce plastic waste in the production of these diagnostic tools. By partnering with Symbio Technologies Ltd for the supply of compostable bio-based material, the company offers a sustainable solution that maintains the functionality of traditional plastic housings while utilizing standard injection molding techniques. This initiative positions Abingdon Health at the forefront of environmentally friendly innovations in the med-tech industry, potentially impacting stakeholders by aligning with global sustainability trends.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Abingdon Health PLC announced that it will release its preliminary results for the year ended 30 June 2025 on 11 November 2025. The company will host a live investor presentation on the same day, open to existing and potential shareholders. This announcement is part of Abingdon Health’s ongoing efforts to engage with stakeholders and provide transparency about its financial performance and strategic direction.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.